Hypersensitivity
Drug research and approvals for hypersensitivity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 1,212 studies of hypersensitivity are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 1,212
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 1
Recruiting Now
Newest start dates first, of 1,212 recruiting on ClinicalTrials.gov ↗- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate…NCT07466498 · Phase 2 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization…NCT07709585 · Phase 2 · Guangzhou University of Traditional Chinese Medicine · starts Nov 30, 2026
- The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in…NCT07027826 · Not applicable · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 19, 2026
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or…NCT07262983 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 19, 2026
- Digital Mindfulness Meditation in Adolescents With Atopic DermatitisNCT07746427 · Not applicable · Weill Medical College of Cornell University · starts Nov 15, 2026
- Light Bulb Stimuli to Reduce Chronic PainNCT07825792 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in…NCT07566117 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes…NCT07939620 · Not applicable · Dr. August Wolff GmbH & Co. KG Arzneimittel · starts Nov 9, 2026
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)NCT07867938 · Phase 2 · Merck Sharp & Dohme LLC · starts Nov 3, 2026
- Zileuton for Food AllergyNCT07935616 · Phase 1 · Abigail Lang · starts Nov 3, 2026
Drug Pipeline
51 approved, 15 in phase 3, 32 in phase 2, 11 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Desloratadine, Cetirizine, Levocetirizine, Chlorpheniramine, Pseudoephedrine, Promethazine, Fexofenadine, Brompheniramine, Loratadine, Clemastine, Rupatadine, Glycerin, Astemizole, Terfenadine, Methapyrilene, Carbinoxamine, Thenalidine, Phenol, Methylpromazine, Epinastine, Cyclizine, Cyproheptadine, Azatadine, Dexbrompheniramine, Azelastine, Pyrilamine, Methdilazine, Bromodiphenhydramine, Meclizine, Acrivastine, Triprolidine, Tripelennamine, Diphenhydramine, Pheniramine, Diphenylpyraline, Ketotifen, Buclizine, Dimenhydrinate, Thiethylperazine, Dextromethorphan and 11 more
- Sodium fluoride
- Phase 3
- Freneslerbart
- Phase 3
- Mevonlerbart
- Phase 3
- Dexamethasone
- Phase 3 Glucocorticoid receptor agonist
- Butenafine
- Phase 3 Squalene monooxygenase inhibitor
- Ligelizumab
- Phase 3 Ig epsilon chain C region inhibitor
- Docetaxel anhydrous
- Phase 3 Tubulin inhibitor
- Paclitaxel
- Phase 3 Tubulin inhibitor
- Dexchlorpheniramine
- Phase 3 Histamine H1 receptor antagonist
- Ciclesonide
- Phase 3 Glucocorticoid receptor agonist
- Triclosan
- Phase 3 Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
- Amoxicillin
- Phase 3 Bacterial penicillin-binding protein inhibitor
- Sodium lauryl sulfate
- Phase 3
- Silicon dioxide
- Phase 3
- Oxomemazine
- Phase 3
- Omalizumab
- Phase 2 Ig epsilon chain C region inhibitor
- Denosumab
- Phase 2 Tumor necrosis factor ligand superfamily member 11 inhibitor
- Albuterol
- Phase 2 Beta-2 adrenergic receptor agonist
- Budesonide
- Phase 2 Glucocorticoid receptor agonist
- Zafirlukast
- Phase 2 Cysteinyl leukotriene receptor 1 antagonist
- Cholecalciferol
- Phase 2 Vitamin D receptor agonist
- Prednisone
- Phase 2 Glucocorticoid receptor agonist
- Formoterol
- Phase 2 Beta-2 adrenergic receptor agonist
- Dupilumab
- Phase 2 Interleukin-4 receptor subunit alpha antagonist
- Tozinameran
- Phase 2 Spike glycoprotein vaccine antigen
- Sodium monofluorophosphate
- Phase 2
- Propolis wax
- Phase 2
- Phosphine silane
- Phase 2
- Remibrutinib
- Phase 2
- Doxylamine
- Phase 2 Histamine H1 receptor antagonist
Showing the 30 furthest along of 58 in trials.
How Its Trials Ended
2,004 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 336 whose ending is known, 54% met their primary endpoint, 4% missed it and 42% stopped early.
- Completed, result not reported1,02051%
- Ongoing39220%
- Status unknown25613%
- Met its primary endpoint1829%
- Stopped: other or unclear744%
- Stopped: enrollment or feasibility362%
- Stopped: sponsor or business decision151%
- Missed its primary endpoint141%
- Stopped: lack of efficacy80%
- Stopped: funding60%
- Stopped: safety10%
FDA Orphan Designations
Approved first, then open designations, newest first| Jul 29, 2011 | Coccidioidin SD Skin Test AntigenFor the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary… | Allermed Labortories, Inc. | Approved |
| Jul 31, 2003 | ZavescaTreatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due… | IC-MedTech Corporation | Approved |
| Mar 19, 1999 | Lidoderm PatchFor relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia. | Teikoku Pharma USA, Inc. | Approved |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 17, 2020 | PalforziaDefatted powder of Arachis hypogaea L., semen (peanuts) | Stallergenes | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA